Luis Puig, Andrey L. Bakulev, Muza M. Kokhan, Alexey V. Samtsov, Vladislav R. Khairutdinov, Maria A. Morozova, . . . Arina V. Zinkina-Orikhan. (2021). Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial. State Scientific Center of Dermatovenereology and Cosmetology.
Chicago Style (17th ed.) CitationLuis Puig, et al. Efficacy and Safety of Netakimab, a Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of a 54-week Randomized Double-blind Placebo-controlled PLANETA Clinical Trial. State Scientific Center of Dermatovenereology and Cosmetology, 2021.
MLA (9th ed.) CitationLuis Puig, et al. Efficacy and Safety of Netakimab, a Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of a 54-week Randomized Double-blind Placebo-controlled PLANETA Clinical Trial. State Scientific Center of Dermatovenereology and Cosmetology, 2021.